OphthaTherapy. Therapies in Ophthalmology https://www.journalsmededu.pl/index.php/ophthatherapy <p>"OphthaTherapy. Therapies in Ophthalmology" (abbr.: OphthaTherapy) is a peer-reviewed scientific quarterly publishing papers in: ophthalmology, ophthalmic surgery (including minimally invasive surgery and laser therapy), pharmacological treatment of eye diseases, including glaucoma, as well as work in the contactology. The journal is on the list of the Polish Ministry of Science and Higher Education. For publishing the article, the author receives 20 points.<br>We encourage you to submit: original papers, review articles, case reports, rapid communication, research letters, hypotheses, meeting proceedings, letter to the editor. There are no submission or processing charges.</p> <p><strong>"OphthaTherapy" accepts submissions in English only. Other language versions may be published as additional ones.</strong><br><br><strong><span lang="en-GB">e-ISSN: </span></strong><span lang="en-GB">2543-9987</span><span lang="en-GB">&nbsp;</span><strong><span lang="en-GB"> &nbsp; &nbsp; &nbsp;ISSN: 2353-7175 &nbsp; &nbsp; &nbsp; DOI: </span></strong><span lang="en-GB">10.24292/01.OT<br><br></span><strong><span lang="en-GB">Indexed in:&nbsp;</span></strong><span lang="en-GB">Polish Journals Master List: <strong>20 points<br></strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Index Copernicus:<strong><strong class="ng-binding">72.79</strong></strong><br></span><span lang="en-GB">&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;Google Scholar<br></span>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Polish Scientific Journal Database<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; ARIANTA<br>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; WorldCat</p> Medical Education sp. z o.o. en-US OphthaTherapy. Therapies in Ophthalmology 2353-7175 <p><strong>Copyright: © Medical Education sp. z o.o.</strong> License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.</p> <p><em>Address reprint requests to: Medical Education, Marcin Kuźma (<a href="mailto:marcin.kuzma@mededu.pl">marcin.kuzma@mededu.pl</a>)</em></p> Hyperreflective dots in optical coherence tomography https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/1866 <p>Optical coherence tomography is a non-invasive and repeatable imaging method of posterior segment of the eye used in medical practice. Hyperreflective dots visible in OCT scans have been reported in various retinal diseases such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion and central serous chorioretinopathy. In the future, HRDs may become a useful biomarker in making treatment decision and monitoring ocular conditions among the patients with mentioned diseases.</p> Katarzyna Paczwa Paulina Szabelska Magdalena Rerych Radosław Różycki Joanna Gołębiewska Copyright (c) 2022 Medical Education sp. z o.o. https://creativecommons.org/licenses/by-nc-nd/4.0 2022-09-30 2022-09-30 9 3 175 179 10.24292/01.OT.300922.1 The role of corneal biomechanical properties assessment in laser vision correction – the introduction https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/2168 <p>The role of corneal biomechanical properties in patients referred to laser vision correction (LVC) is currently being raised. Understanding of corneal biomechanics may support the proper selection of refractive surgery candidates, improve the refractive outcomes and safety of refractive procedures. The Ocular Response Analyzer (ORA) and Corvis ST are commonly used devices to assess corneal biomechanical parameters in LVC. The vertical corneal incisions have a greater impact on corneal biomechanics weakening than horizontal incisions. Maintaining the high biomechanical strength of the cornea following LVC can decrease the potential risk of postoperative ectasia.</p> Zofia Pniakowska Piotr Jurowski Joanna Wierzbowska Copyright (c) 2022-09-30 2022-09-30 9 3 183 186 10.24292/01.OT.300922.2 The use of pilocarpine in the treatment of presbyopia https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/2169 <p>Presbyopia is a physiological process of progressive loss of accommodation, which leads to a deterioration in the ability to focus vision on objects at different distances. This is now thought to be a direct consequence of two causes: the design of the transparent lens and the way it has to change shape to allow focusing, and the instability of proteins over very long periods of time. In recent years, various substances that temporarily narrow the pupil, causing a pinhole effect, have been intensively investigated to allow improved near vision acuity. The most commonly researched is 1.25% pilocarpine solution. The substance itself has been known for more than 100 years, with a well-documented hypotensive effect and numerous side effects. However, the reduced concentration and less frequent dosing, as well as the addition of drugs with anti-inflammatory effects currently being studied, offer hope for efficacy in the treatment of presbyopia. The results of the studies so far are promising. Researchers point to improved near visual acuity and a low rate of mild side effects. In the future, we will find out whether the optimistic observations mainly in short-term studies will also be effective and applicable in broad practice.</p> Dorota Szumny Copyright (c) 2022-09-30 2022-09-30 9 3 189 193 10.24292/01.OT.300922.3 Dexpanthenol in the treatment of corneal disorders and injuries https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/2170 <p>Dexpanthenol – a precursor to vitamin B<sub>5</sub> – is a compound of natural origin that has a long-known beneficial effect on skin and mucous membrane hydration and epithelial healing. Its anti-inflammatory activity is also used in treatment. Its effects on superficial tissues have been observed in numerous in vitro and in vivo studies, but the exact mechanism of action has not yet been understood. In ophthalmology, dexpanthenol is a well-known and widely used drug in patients with acute and chronic diseases of the ocular surface, as well as for treating the sequelae of corneal injuries.</p> Dorota Szumny Marta Misiuk-Hojło Copyright (c) 2022-09-30 2022-09-30 9 3 195 199 10.24292/01.OT.300922.4 The outcome of ciliary body ablation with diode laser contact transscleral cyclophotocoagulation in 6 months follow-up https://www.journalsmededu.pl/index.php/ophthatherapy/article/view/1839 <p>The aim of the study is to analyse the postoperative results of continuous wave, transscleral cyclophotocoagulations (CW-TSCPC) in 6 months follow-up for patients with refractory glaucoma.</p> <p><strong>Material and methods</strong>: We retrospectively reviewed 58 records of patients who underwent the transscleral cyclophotocoagulation because of refractory glaucoma at the Department of Ophthalmology, Poznan University of Medical Sciences, Poland, between 2016 and 2022. All patients underwent ophthalmological examination at baseline and during follow-up visits including best-corrected visual acuity, intraocular pressure measurement (IOP), slit-lamp examination, visual field and optical coherence tomography examination of the retinal nerve fiber layer (OCT RNFL). Follow-up time was 6 months.</p> <p><strong>Results</strong>: We analyzed a group of 58 patients (28 women and 30 men, average age of 62). Majority of patients (41 eyes, 70.69%) had secondary open angle glaucoma. There were no serious complications of the CW-TSCPC procedure. We achieved IOP normalization (IOP below 22 mmHg) in 81.03% of eyes in 1 month follow-up, in 81.08% after 2 months, and in 72.41% after 6 months. Mean IOP reduction was 53.47%, 47.71%, and 47.65% from baseline at 1, 2, and 6 months, respectively. The number of medications taken by patients was lowered of 74.14%, 70.27% and 68.97% after 1, 2 and 6 months respectively. 17 eyes (29.31%) required additional surgical interventions within 6 months.</p> <p><strong>Conclusions</strong>: CW-TSCPC is an effective and safe procedure. It allows lowering of IOP and reduction of drugs number administrated by patients with various types of glaucoma during 6 months follow-up. The procedure is technically easy and with well-controlled postoperative complications.</p> Weronika Mularska Agata Brązert Jarosław Kocięcki Copyright (c) 2022 Medical Education sp. z o.o. https://creativecommons.org/licenses/by-nc-nd/4.0 2022-09-30 2022-09-30 9 3 202 205 10.24292/01.OT.300922.5